Form 4: MaxCyte CFO Douglas Swirsky Acquires Shares and Options
SEC Form 4 Filing
Douglas Swirsky, CFO of MaxCyte, Inc., reports acquisition of common stock and stock options.
Summary
- On March 15, 2024, Douglas J Swirsky, the Chief Financial Officer of MaxCyte, Inc., acquired 81,250 shares of common stock.
- These shares were granted as restricted stock units (RSUs), each representing a right to receive one share of MaxCyte's common stock.
- 25% of the RSUs will vest on March 15, 2025, with the remaining portion vesting in three equal annual installments, contingent upon continued service.
- Swirsky also acquired options to purchase 225,000 shares of common stock at an exercise price of $4.31.
- 25% of these options will vest on March 15, 2025, and the remainder will vest in 36 equal monthly installments, also subject to continued service.
- Following these transactions, Swirsky directly owns 81,250 shares of common stock and options for 225,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock and option grants to the CFO. It doesn't inherently indicate positive or negative news, but rather a routine part of executive compensation.
Positives
- The acquisition of shares and options by the CFO could be interpreted as a sign of confidence in the company's future prospects.
- The vesting schedules for both the RSUs and options incentivize the CFO to remain with the company for the long term.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules suggest a multi-year commitment from the CFO.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. This filing indicates changes in the CFO's holdings of MaxCyte stock and options.
Stakeholder Impact
- The vesting schedules for the RSUs and options incentivize the CFO to remain with the company for the long term, which could benefit shareholders.
- The increased ownership stake aligns the CFO's interests more closely with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of transaction: Acquisition of common stock (RSUs) and stock options. |
| 03/15/2025 | First vesting date for 25% of RSUs and stock options. |
| 03/14/2034 | Expiration date for the employee stock options. |
| 03/19/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.